ctDNA-Guided Chemo Does Not Yield RFS Benefit in Stage III Colon Cancer
Adjuvant chemotherapy decisions based on ctDNA status did not improve recurrence-free survival in stage III colon cancer.
Related Articles
SUPRAME Trial Seeks to Establish IMA203 as the First TCR-Based Therapy for Cutaneous Melanoma
The phase 3 SUPRAME trial is comparing IMA203 vs investigator’s choice of therapy in patients with pretreated unresectable or metastatic cutaneous melanoma.
Updated EHA-EMN Guidelines Include Melphalan Flufenamide for R/R Myeloma
The EHA-EMN guidelines now include melphalan flufenamide for certain patients with relapsed/refractory multiple myeloma.
Nogapendekin Alfa Inbakicept Plus BCG Approved in UK for BCG-Unresponsive NMIBC With CIS
The combination of nogapendekin alfa inbakicept and BCG is now approved in the United Kingdom for the treatment of patients with NMIBC with CIS.
Forbes Names Roswell Park One of America’s Best Employers for Women 2025
A New York cancer center appears on list for second consecutive year, based on anonymous employee surveys
Menin Inhibitors Are Poised to Expand Targeted Therapeutics to Broader AML Populations
Naval G. Daver, MD, and Eytan M. Stein, MD, discuss how menin inhibitors may transform the treatment paradigm in NPM1-mutant and NUP98 fusion AML.
Efficacy of Upfront Panitumumab Plus Intensified Chemo Falls Short in Liver-Limited, Unresectable mCRC
Panitumumab plus FOLFIRINOX or mFOLFOX6 did not elicit meaningful responses in previously untreated, liver-limited, RAS/BRAF wild-type unresectable mCRC.
Coordinated Care in Breast Oncology
In this series of OncChats: Coordinated Care in Breast Oncology, Jason Ye, MD, and Daphne B. Stewart, MD, of Keck Medicine of USC, discuss the…
How Passion for Healing and Health Care Equity Expands Access to Innovative Therapies: With D. Ross Camidge, MD, PhD; and Brandon Blue, MD
Drs Camidge and Blue discussed Dr Blue’s journey into practicing medicine, and speciaffly how he settled on treating malignant hematologic conditions.
Dr Hayne on the Rationale for Evaluating Mitomycin Plus BCG vs BCG Alone in NMIBC
Dickon Hayne, MD, FRCS, MBBS, discusses the rationale for evaluating the addition of mitomycin to BCG in non–muscle-invasive bladder cancer.
Dr Kahlon on the Availability of Generic Eltrombopag for Anemia & Thrombocytopenia
Kanwarpal S. Kahlon, MD, discusses the benefits of the availability of generic eltrombopag formulations for aplastic anemia and immune thrombocytopenia.